Literature DB >> 33247492

Ambulatory thyroidectomy is safe and beneficial in papillary thyroid carcinoma: Randomized controlled trial.

Zeyu Zhang1, Fada Xia1, Wenlong Wang1, Bo Jiang1, Lei Yao1, Yun Huang2, Xinying Li1.   

Abstract

BACKGROUND: Currently, no randomized controlled trial has been performed to investigate the safety profiles, economic benefit and mental health of ambulatory thyroidectomy in patients with papillary thyroid carcinoma (PTC).
METHODS: Patients diagnosed with PTC were enrolled in this study and were randomly assigned to ambulatory group and control group. The safety profiles, economic benefit and mental health were investigated.
RESULTS: Four hundred and eleven patients completed the study. There was no significant difference in demographic or tumor index. The incidence of complications was not significantly different (P = .631). The economic cost was significantly lower (P < .001) and hospitalization was significantly shorter (P < .001) in ambulatory group. No significant difference was shown in depression (P = .758) and stress disorder (P = .390). However, the ambulatory group showed a higher point of anxiety (P < .001).
CONCLUSION: The ambulatory thyroidectomy is safe in patients with PTC, with significant benefits of economic cost and hospitalization.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  ambulatory surgery; papillary thyroid carcinoma; postoperative complication; thyroidectomy

Year:  2020        PMID: 33247492     DOI: 10.1002/hed.26557

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

1.  Ambulatory Endoscopic Thyroidectomy via a Chest-Breast Approach Has an Acceptable Safety Profile for Thyroid Nodule.

Authors:  Zeyu Zhang; Fada Xia; Xinying Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-20       Impact factor: 5.555

Review 2.  Risk of hematoma after hemithyroidectomy in an outpatient setting: a systematic review and meta-analysis.

Authors:  Karin Jeppesen; Caroline Moos; Tórhild Holm; Andreas Kristian Pedersen; Helene Skjøt-Arkil
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-03-16       Impact factor: 3.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.